EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Metastasis-directed therapy in addition to definitive locoregional radiotherapy for De novo metastatic nasopharyngeal carcinoma: a retrospective cohort study

Sarbani Ghosh Laskar, Anuj Kumar, Rahat Malhotra, Shwetabh Sinha, Samarpita Mohanty, Kumar Prabhash, Amit Joshi, Nandini Menon, Omshree Shetty, Anuradha Chougule, Ashwini Budrukkar, Monali Swain und 17 weitere

Clinical and Translational Radiation Oncology · 2027-01 · 62 · 101338

DOI: 10.1016/j.ctro.2026.101338 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical and Translational Radiation Oncology, 2027-01. Verfasst von Sarbani Ghosh Laskar und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

De novo metastatic nasopharyngeal carcinoma (mNPC) carries a poor prognosis with systemic therapy alone. Locoregional radiotherapy (LRRT) improves survival in chemotherapy-responsive patients, but the incremental role of metastasis-directed therapy (MDT) remains undefined.

Methods

This retrospective cohort included 54 patients with de novo mNPC treated between 2013 and 2024 at a tertiary cancer centre. All received platinum-based induction chemotherapy followed by definitive LRRT; selected patients underwent MDT to metastatic sites. Overall survival (OS), recurrence-free survival (RFS) and distant recurrence-free survival (DRFS) were estimated by Kaplan-Meier methods, with Cox regression for univariable and multivariable analysis.

Results

At a median follow-up of 27 months, 2-year OS, RFS and DRFS were 67.5%, 45.4% and 52.7%. MDT was associated with improved 2-year OS (92.3% vs 55.2%; p = 0.0069), RFS (81.9% vs 28.2%; p < 0.001) and DRFS (93.8% vs 35.0%; p < 0.001). On multivariable analysis MDT remained associated with improved RFS (HR 0.27, 95% CI 0.08-0.98; p = 0.047), with consistent estimates in a 2-month landmark analysis (HR 0.26, 95% CI 0.075-0.90) and with MDT modelled as a time-varying covariate (HR 0.17, 95% CI 0.040-0.76); the association with OS was not statistically significant (HR 0.25, 95% CI 0.06-1.13; p = 0.072). Oligometastatic disease was more frequent among patients receiving MDT (88% vs 41%). The association was most evident in the oligometastatic subgroup. In exploratory analyses, detectable post-treatment plasma EBV DNA and elevated post-LRRT PET SUV were associated with inferior survival.

Conclusion

In chemotherapy-responsive de novo mNPC treated with definitive LRRT, consolidative MDT was associated with improved disease control in multivariable, landmark and time-varying analyses, with a directionally consistent but non-significant association with OS. As residual confounding cannot be excluded, these findings support prospective evaluation in selected patients.

Schlagwörter

Stichwörter der Autor:innen

EBV DNALocoregional radiotherapyMetastasis-directed therapyMetastatic NPCNasopharyngeal carcinomaOligometastatic disease

Autor:innen und Institutionen

  • Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
  • Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
  • Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
  • Department of Head and Neck Surgery, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Zitieren

APA

Laskar, S. G., Kumar, A., Malhotra, R., Sinha, S., Mohanty, S., Prabhash, K., Joshi, A., Menon, N., Shetty, O., Chougule, A., Budrukkar, A., Swain, M., Noronha, V., Shah, M., Dhanawat, A., Pantvaidya, G., Nair, D., Thiagarajan, S., Dravid, C., …, & Chaturvedi, P. (2027). Metastasis-directed therapy in addition to definitive locoregional radiotherapy for De novo metastatic nasopharyngeal carcinoma: a retrospective cohort study. Clinical and Translational Radiation Oncology, 62, 101338. https://doi.org/10.1016/j.ctro.2026.101338

Vancouver

Laskar SG, Kumar A, Malhotra R, Sinha S, Mohanty S, Prabhash K, et al. Metastasis-directed therapy in addition to definitive locoregional radiotherapy for De novo metastatic nasopharyngeal carcinoma: a retrospective cohort study. Clinical and Translational Radiation Oncology. 2027;62:101338. doi:10.1016/j.ctro.2026.101338

BibTeX
@article{Laskar2027,
  author = {Laskar, Sarbani Ghosh and Kumar, Anuj and Malhotra, Rahat and Sinha, Shwetabh and Mohanty, Samarpita and Prabhash, Kumar and Joshi, Amit and Menon, Nandini and Shetty, Omshree and Chougule, Anuradha and Budrukkar, Ashwini and Swain, Monali and Noronha, Vanita and Shah, Minit and Dhanawat, Aditya and Pantvaidya, Gouri and Nair, Deepa and Thiagarajan, Shivakumar and Dravid, Chandrashekhar and Tuljapurkar, Vidisha and Deshmukh, Anuja and Mittal, Rishi and Vaish, Richa and Prabhu, Rukmini and Singh, Arjun and Nair, Sudhir and Joshi, Poonam and Shetty, Rathan and Chaturvedi, Pankaj},
  title = {Metastasis-directed therapy in addition to definitive locoregional radiotherapy for De novo metastatic nasopharyngeal carcinoma: a retrospective cohort study},
  journal = {Clinical and Translational Radiation Oncology},
  year = {2027},
  volume = {62},
  pages = {101338},
  doi = {10.1016/j.ctro.2026.101338}
}
Kostenlos starten →